Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
70 hedge funds and large institutions have $105M invested in Syros Pharmaceuticals, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 17 closing their positions.
747% more call options, than puts
Call options by funds: $144K | Put options by funds: $17K
73% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less capital invested
Capital invested by funds: $112M → $105M (-$6.72M)
7% less funds holding
Funds holding: 75 → 70 (-5)
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Exome Asset Management
New York
|
+$836K |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$571K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$542K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$409K |
| 5 |
PCM
Prelude Capital Management
New York
|
+$212K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DMKJ
David M. Knott Jr
|
-$1.25M |
| 2 |
Millennium Management
New York
|
-$1.04M |
| 3 |
Goldman Sachs
New York
|
-$968K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$810K |
| 5 |
Jane Street
New York
|
-$701K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
YIH
76
Y-Intercept (HK)
Hong Kong
| – | -$98.8K | -18,463 | Closed |
|
|
BHCM
77
Brevan Howard Capital Management
St. Helier,
Jersey
| – | -$85.8K | -16,036 | Closed |
|
78
CIBC Asset Management
Toronto,
Ontario, Canada
| – | -$82.4K | -15,398 | Closed |
|
79
Squarepoint
New York
| – | -$79.7K | -14,890 | Closed |
|
80
American Century Companies
Kansas City,
Missouri
| – | -$72.9K | -13,624 | Closed |
|
|
VF
81
Virtu Financial
New York
| – | -$64K | -12,030 | Closed |
|
|
OAC
82
OMERS Administration Corp
Toronto,
Ontario, Canada
| – | -$63.1K | -11,800 | Closed |
|
83
Two Sigma Advisers
New York
| – | -$61.8K | -11,550 | Closed |
|
|
XT
84
XTX Topco
George Town,
Cayman Islands
| – | -$58.6K | -10,949 | Closed |
|
85
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$3 | -613 | Closed |
|
|
IA
86
IFP Advisors
Tampa,
Florida
| – | -$2.34K | -438 | Closed |
|
87
Fidelity Investments
Boston,
Massachusetts
| – | -$380 | -71 | Closed |
|
SYRS Hedge Fund Activity: Q2 2024 in Review
70 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q2 2024, worth a combined $105M — down 6% from $112M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of SYRS and 12 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 19 added.
The largest buyer was Exome Asset Management, opening a new position worth an estimated $836K. The largest seller was David M. Knott Jr, exiting entirely with an estimated $1.25M sold.
- 70 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q2 2024, down from 75 in Q1 2024.
- Funds reported $105M of Syros Pharmaceuticals, Inc. Common Stock stock for Q2 2024, down 6% quarter-over-quarter.
- 12 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q2 2024 and 17 closed out, a net change of -5 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q2 2024 was Exome Asset Management, an estimated $836K added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q2 2024 was David M. Knott Jr, an estimated $1.25M sold.
Based on aggregated 13F filings for Q2 2024.